Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria

Sponsor
Memorial Sloan Kettering Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04501419
Collaborator
Obafemi Awolowo University Teaching Hospital (Other)
600
1
2
44.8
13.4

Study Details

Study Description

Brief Summary

The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies on women that present to the hospital with a suspicious breast mass. Before performing biopsies on patients, the Nigerian radiologists will have already successfully completed a competency-based mobile health ultrasound-guided breast biopsy-training program. This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: US-guided breast biopsy
  • Other: Ultrasound-guided breast biopsy training program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria
Actual Study Start Date :
Oct 5, 2019
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Trained radiologists

Trainers will successfully train Nigerian radiologists

Other: Ultrasound-guided breast biopsy training program
This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients

Experimental: Patients with a suspicious breast mass

Women that present to the hospital with a suspicious breast mass

Procedure: US-guided breast biopsy
During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.

Outcome Measures

Primary Outcome Measures

  1. Accuracy of US-guided breast biopsy in Nigeria compared to reference standard surgical excision [12 months]

    US-guided breast biopsies accuracy measurements will be reported using surgical pathology as the reference standard. Specifically we will report accuracy, positive predictive value, negative predictive value, sensitivity and specificity.

Secondary Outcome Measures

  1. Complication rates from US-guided breast biopsy compared to reference values reported in the literature. [12 months]

    To determine if the complication rate of US-guided breast biopsies performed by the trained Nigerian radiologists is equivalent to reference values reported in the literature.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18 and older female

  • Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis.

Exclusion Criteria:
  • Participants unwilling to sign consent

  • Participants under the age of 18.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC) Ile-Ife Nigeria

Sponsors and Collaborators

  • Memorial Sloan Kettering Cancer Center
  • Obafemi Awolowo University Teaching Hospital

Investigators

  • Principal Investigator: Adeleye Omisore, MD, Obafemi Awolowo University Teaching Hospitals

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT04501419
Other Study ID Numbers:
  • ERC/2019/10/05
  • 18-114
First Posted:
Aug 6, 2020
Last Update Posted:
Aug 10, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 10, 2022